Shares of Corcept Therapeutics (CORT), a commercial-stage biopharmaceutical company focused on cortisol modulation, sank 20% on Friday. The stock dropped $21.64 to end at $85.86 with volume of roughly 2.86 million shares, a relative volume of 3.78 times the one-month avera
Shares of Corcept Therapeutics (CORT), a commercial-stage biopharmaceutical company focused on cortisol modulation, sank 20% on Friday.
The stock dropped $21.64 to end at $85.86 with volume of roughly 2.86 million shares, a relative volume of 3.78 times the one-month average
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
